Home > Documents in Process > Nucleus Basalis of Meynert: Functional Connectivity and Morphometry in Alzheimer's Disease and Frontotemporal Dementia > print

001     283148
005     20260108145752.0
024 7 _ |a 10.1002/alz70856_105620
|2 doi
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
037 _ _ |a DZNE-2026-00044
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Kindler, Christine
|0 P:(DE-2719)9000373
|b 0
|e First author
|u dzne
111 2 _ |a Alzheimer’s Association International Conference
|g AAIC 25
|c Toronto
|d 2025-07-27 - 2025-07-31
|w Canada
245 _ _ |a Nucleus Basalis of Meynert: Functional Connectivity and Morphometry in Alzheimer's Disease and Frontotemporal Dementia
260 _ _ |c 2025
336 7 _ |a Abstract
|b abstract
|m abstract
|0 PUB:(DE-HGF)1
|s 1767880647_14467
|2 PUB:(DE-HGF)
336 7 _ |a Conference Paper
|0 33
|2 EndNote
336 7 _ |a INPROCEEDINGS
|2 BibTeX
336 7 _ |a conferenceObject
|2 DRIVER
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|m journal
336 7 _ |a Output Types/Conference Abstract
|2 DataCite
336 7 _ |a OTHER
|2 ORCID
520 _ _ |a The nucleus basalis of Meynert (NBM) is crucial for learning, attention, and memory. While its involvement in Alzheimer's disease (AD) has been widely reported, the role in frontotemporal dementia (FTD) remains unclear. Here we examined NBM functional connectivity (FC) as well as NBM and cortical volume changes in AD, healthy controls (HC), and FTD subtypes: behavioral variant FTD (bvFTD), unclassified primary progressive aphasia (PPA), progressive nonfluent aphasia (PNFA), semantic dementia (SemD), and progressive logopenic aphasia (PLA).Resting-state fMRI and T1-weighted scans were collected from HC (n = 66), individuals with AD (n = 50), bvFTD (n = 63), PLA (n = 18), PPA (n = 20), PNFA (n = 32), and SemD (n = 15). We performed seed-based FC analyses in FSL with left and right NBM as seeds. We compared HC with AD (cluster-based threshold z > 2.3, p < 0.05). Significant clusters were used to extract mean FC for the other groups. We then compared FC values and normalized NBM volumes across HC and FTD subtypes using the Kruskal-Wallis test, followed by Bonferroni-corrected pairwise comparisons where applicable. Voxel-based morphometry (VBM) was conducted to explore cortical atrophy patterns.HC showed stronger NBM connectivity than AD in the hippocampus/parahippocampal gyrus, frontal pole, paracingulate cortex, precuneus, and lateral occipital cortex (Figure 1, left NBM results). Across HC and FTD subtypes, we found significant group differences for the paracingulate (H = 36.15, p < 0.001) and lateral occipital cortex (H = 18.25, p = 0.003). Connectivity was higher in bvFTD, PPA, and LPA than in HC, with the strongest effect for bvFTD in the paracingulate cortex (r = 0.48) and moderate effects across other contrasts (r = 0.28-0.42, all p < 0.020). Volumetric analyses indicated no significant group differences in NBM volumes but distinct cortical atrophy patterns: PNFA, PLA, and PPA exhibited temporal- frontal atrophy similar to AD, while bvFTD showed predominantly frontal and SemD primarily temporal atrophy.Differential functional connectivity of the NBM and distinct cortical atrophy patterns were observed between HC and AD and between HC and FTD subtypes. Ongoing analyses on subgroup comparisons and integration of cognitive assessments aim to elucidate these relationships and their clinical implications.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 354 - Disease Prevention and Healthy Aging (POF4-354)
|0 G:(DE-HGF)POF4-354
|c POF4-354
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Alzheimer Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Alzheimer Disease: pathology
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: pathology
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: diagnostic imaging
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: physiopathology
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Biomarkers
|2 MeSH
650 _ 2 |a Basal Nucleus of Meynert: diagnostic imaging
|2 MeSH
650 _ 2 |a Basal Nucleus of Meynert: pathology
|2 MeSH
650 _ 2 |a Basal Nucleus of Meynert: physiopathology
|2 MeSH
650 _ 2 |a Aphasia, Primary Progressive
|2 MeSH
693 _ _ |0 EXP:(DE-2719)DELCODE-20140101
|5 EXP:(DE-2719)DELCODE-20140101
|e Longitudinal Cognitive Impairment and Dementia Study
|x 0
693 _ _ |0 EXP:(DE-2719)DESCRIBE-FTD-20160101
|5 EXP:(DE-2719)DESCRIBE-FTD-20160101
|e DZNE Clinical Registry Study on Frontotemporal Dementia (FTD)
|x 1
693 _ _ |0 EXP:(DE-2719)DANCER-20150101
|5 EXP:(DE-2719)DANCER-20150101
|e Degeneration Controls and Relatives
|x 2
700 1 _ |a Gillis, Grace
|b 1
700 1 _ |a Bhalerao, Gaurav V
|b 2
700 1 _ |a Andersson, Jesper L. R.
|b 3
700 1 _ |a McCarthy, Paul
|b 4
700 1 _ |a Miklitz, Carolin
|0 P:(DE-2719)2810438
|b 5
|u dzne
700 1 _ |a Stoecker, Tony
|0 P:(DE-2719)2810538
|b 6
|u dzne
700 1 _ |a Petzold, Gabor C
|0 P:(DE-2719)2810273
|b 7
|u dzne
700 1 _ |a Griffanti, Ludovica
|b 8
773 _ _ |a 10.1002/alz70856_105620
|g Vol. 21, no. S2, p. e105620
|0 PERI:(DE-600)2201940-6
|n S2
|p e105620
|t Alzheimer's and dementia
|v 21
|y 2025
|x 1552-5260
856 4 _ |u https://pub.dzne.de/record/283148/files/DZNE-2026-00044.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/283148/files/DZNE-2026-00044.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9000373
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2810438
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2810538
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2810273
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-354
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Prevention and Healthy Aging
|x 1
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-06
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies (Bonn)
|l Patient Studies (Bonn)
|x 0
920 1 _ |0 I:(DE-2719)1013026
|k AG Stöcker
|l MR Physics
|x 1
920 1 _ |0 I:(DE-2719)1013020
|k AG Petzold
|l Vascular Neurology
|x 2
980 _ _ |a abstract
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a journal
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a I:(DE-2719)1013026
980 _ _ |a I:(DE-2719)1013020
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21